Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma

Haematologica

Volumn 99, Issue 3, 2014, Pages

  Lok, Anne ^a   Mocquard, Julie ^a   Bourcier, Jessie ^a   Redelsperger, Laurence ^a   Bonnet, Antoine ^a   Chauvin, Cecile ^a   Thomaré, Patrick ^a   Mahé, Beatrice ^a   Touzeau, Cyrille ^a   Moreau, Philippe ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

ASCT; Multiple myeloma; Subcutaneous bortezomib; VTD

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; MYELOMA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT PLANNING; TREATMENT RESPONSE; ADULT; AGED; AUTOTRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; PYRAZINES; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84895738375     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.100396     Document Type: Letter

References (10)

1. Moreau P, Avet-Loiseau H, Harousseau J-L, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29(14):1898-906.
2. Moreau P, san Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi133-7.
3. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-85.
4. Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118(22):5752-8.
5. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589-96.
6. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9-19.
7. Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Lorraine Chrétien M, et al. Consolidation with VTD significantly improves the complete remission rate and time to progression following VTD induction and single autologous stem cell transplantation in multiple myeloma. Leukemia. 2013;27(11):2242-4.
8. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12(5):431-40.
9. Lamm W, Drach-Schauer B, Eder S, Drach J. Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma. Oncology. 2013;85(4):223-7.
10. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.